ArticleBMC medical imaging2026
Individualized metabolic brain network alterations in diffuse large B-cell lymphoma: an
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate cross-sectional differences in individualized metabolic brain network topology between patients with diffuse large B-cell lymphoma (DLBCL) and healthy controls, and to explore the associations between network topology and cognitive performance.
methodsA total of 104 patients with DLBCL and 33 healthy controls were prospectively enrolled. All participants underwent whole-body
resultsWe included 137 participants: 104 patients (mean age, 55.6 ± 11.7 years; 57 males) and 33 healthy controls (mean age, 50.3 ± 11.8 years; 17 males). Compared with controls, both baseline and post-chemotherapy patients showed significantly lower MMSE and MoCA scores (P < 0.001). There were no significant differences in cognitive scale scores between the two patient groups. Meanwhile, all groups exhibited small-world properties (γ > 1, λ ≈ 1, σ > 1), with no significant differences in global network metrics (P > 0.05). At the nodal level, baseline patients showed increased nodal degree and efficiency specifically in frontal regions, and decreased betweenness centrality in bilateral parietal regions. In cross-sectional comparisons, post-chemotherapy patients exhibited decreased degree centrality and nodal efficiency in prefrontal regions compared with baseline. In contrast, temporal, occipital, and selected subcortical regions showed increased nodal degree or efficiency. Furthermore, nodal degree, efficiency, and betweenness centrality in these regions were significantly correlated with cognitive scores.
conclusionDLBCL patients maintained global network organization but demonstrated specific regional topological changes compared to healthy controls. The observed nodal differences between baseline and post-chemotherapy patients were correlated with cognitive performance. Individualized
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.